Kymriah Side Effects: Cytokine Release Syndrome, Toxicity, Infections. Last 30 August 2017, the Food and Drug Administration (FDA) approved Kymriah cell therapy to treat children and young adults (up to 25 years of age) with B-cell acute lymphoblastic leukemia.
How is the treatment administered and what side effects should patients be aware of? Apparently, the treatment administration involves the collection of T-cells from the patient, modifying it, and injecting it back. More details from the FDA media release:
The patient’s T-cells are collected and sent to a manufacturing center where they are genetically modified to include a new gene that contains a specific protein (a chimeric antigen receptor or CAR) that directs the T-cells to target and kill leukemia cells that have a specific antigen (CD19) on the surface. Once the cells are modified, they are infused back into the patient to kill the cancer cells.